nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Unipolar Depression"

 

A Randomized Proof-of-Mechanism Trial Applying the ‘Fast-Fail’ Approach to Evaluating κ-Opioid Antagonism as a Treatment for Anhedonia
April 15, 2020   

The first Fast-Fail trial funded by the National Institute of Mental Health has identified a target for treating anhedonia. The Fast-Fail Trials initiative aims to improve early phase drug development...
 Continue reading (Members only)
Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus
April 9, 2020   

With the rising rates of COVID-19 (i.e., severe acute respiratory syndrome coronavirus 2) infection and hospitalization across the world, frontline health care workers will continue to face an overwhelming workload throughout the course of this pandemic. This workload, along with the depletion of personal protection equipment, widespread media coverage, lack of specific drugs and feelings of being inadequately supported may contribute to adverse psychological reactions...
 Continue reading
Severe Clinical Consequences of Childhood Abuse and Neglect
February 10, 2020   

l infarction, cerebrovascular disease, type 2 diabetes, asthma, cancer, and overall lowered life expectancy. In this article, the authors review the current state of research regarding the association of early childhood abuse/neglect with development of psychiatric illness, particularly mood disorders such as...
 Continue reading (Members only)
Psilocybin Receives Breakthrough Therapy Designation for Major Depressive Disorder
January 22, 2020   

The Food and Drug Administration (FDA) has granted psilocybin Breakthrough Therapy Designation for the second time. This latest FDA designation goes to...
 Continue reading (Members only)
Meta-analysis Shows No Effect of Omega-3 for Prevention or Treatment of Depression and Anxiety
November 25, 2019   

Many individuals suffering from mental health disorders, such as depression and anxiety, turn to the use of complementary and alternative medications (CAMs). One such CAM is polyunsaturated fatty acids...
 Continue reading (Members only)
Positive Data for GABA Modulator as Treatment for Depression
September 21, 2019   

Commonly-used antidepressant medications (SSRIs and SNRIs) work on the monoaminergic system and all-too-often are ineffective for patients with major depressive disorder (MDD). Additionally, SSRIs and SNRIs can take months to have a full antidepressant effect. Over the past few years...
 Continue reading (Members only)
Olanzapine Augmentation During Remission From Psychotic Depression: Benefit vs. Risk
September 15, 2019   

A recently published randomized trial found that among patients with psychotic depression in remission, continuing sertraline plus olanzapine reduced the risk of relapse over when compared with sertraline ...
 Continue reading (Members only)
Metformin Use During Pregnancy May Affect Growth of Offspring
September 12, 2019   

A recent systematic review and meta-analysis compares metformin to insulin for treatment of gestational diabetes mellitus and how it each may alter the growth trajectories from the time of fetal exposure to childhood. Despite...
 Continue reading (Members only)
National Survey on Drug Use and Health: Trends in Marijuana Use, Prescription Drug Misuse, Major Depressive Episodes, and Other Health Measures
September 8, 2019   

The Substance Abuse and Mental Health Services Administration (SAMSA) recently released their annual national report, based on data from the 2018 National Survey on Drug Use and Health (NSDUH)...
 Continue reading
Degree of Serotonin Reuptake Inhibition and Risk of Ischemic Stroke
September 3, 2019   

Untreated depression has been reported to be associated with cardiovascular disease, thus patients with increased risk for ischemia have been prescribed antidepressants. Previous research also suggests that strong inhibitors may reduce the risk of arterial ischemic activity, however...
 Continue reading (Members only)
123456789
Top of Page